JP2011518883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518883A5 JP2011518883A5 JP2011507559A JP2011507559A JP2011518883A5 JP 2011518883 A5 JP2011518883 A5 JP 2011518883A5 JP 2011507559 A JP2011507559 A JP 2011507559A JP 2011507559 A JP2011507559 A JP 2011507559A JP 2011518883 A5 JP2011518883 A5 JP 2011518883A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- compound
- aromatase inhibitor
- breast cancer
- cdb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 14
- -1 monoalkylamino Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 10
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 7
- 239000003886 aromatase inhibitor Substances 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Chemical group 0.000 claims 4
- JVBGZFRPTRKSBB-MJBQOYBXSA-N Telapristone acetate Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 229960003437 aminoglutethimide Drugs 0.000 claims 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 2
- 229960002932 anastrozole Drugs 0.000 claims 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 229960000255 exemestane Drugs 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 229960003881 letrozole Drugs 0.000 claims 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000008467 tissue growth Effects 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 claims 1
- 102100025803 Progesterone receptor Human genes 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4845208P | 2008-04-28 | 2008-04-28 | |
| US61/048,452 | 2008-04-28 | ||
| PCT/US2009/041836 WO2009134723A1 (en) | 2008-04-28 | 2009-04-27 | Pregesteron antagonists such as cdb-4124 in the treatment of breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011518883A JP2011518883A (ja) | 2011-06-30 |
| JP2011518883A5 true JP2011518883A5 (enExample) | 2012-06-07 |
| JP5576362B2 JP5576362B2 (ja) | 2014-08-20 |
Family
ID=40758440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507559A Expired - Fee Related JP5576362B2 (ja) | 2008-04-28 | 2009-04-27 | 乳癌を治療するための組成物および方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20110053900A1 (enExample) |
| EP (2) | EP2974772A1 (enExample) |
| JP (1) | JP5576362B2 (enExample) |
| KR (1) | KR101349737B1 (enExample) |
| CN (1) | CN102099040B (enExample) |
| AR (1) | AR071419A1 (enExample) |
| AU (1) | AU2009241360B2 (enExample) |
| BR (1) | BRPI0911112A2 (enExample) |
| CA (1) | CA2722637C (enExample) |
| CL (1) | CL2009001011A1 (enExample) |
| EA (1) | EA019224B1 (enExample) |
| IL (2) | IL208845A (enExample) |
| ME (1) | ME01122B (enExample) |
| MX (1) | MX2010011273A (enExample) |
| MY (1) | MY161549A (enExample) |
| NI (1) | NI201000184A (enExample) |
| NZ (1) | NZ589534A (enExample) |
| TW (1) | TWI539953B (enExample) |
| UA (1) | UA101192C2 (enExample) |
| WO (1) | WO2009134723A1 (enExample) |
| ZA (1) | ZA201007648B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011157443A1 (en) | 2010-06-17 | 2011-12-22 | N.V. Organon | (11b,17a)-11-(4-(2-11c-acetyl)phenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one |
| UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| EP2763680A4 (en) | 2011-10-04 | 2015-05-20 | Invivis Pharmaceuticals Inc | METHODS AND SYSTEMS FOR IDENTIFYING AND TREATING ANTIPROGESTIN-SENSITIVE TUMORS |
| FR2997628B1 (fr) * | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone |
| HK1216513A1 (zh) | 2013-03-15 | 2016-11-18 | 阿普雷奇亚制药有限责任公司 | 包含左乙拉西坦的快速分散劑型 |
| US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| HU230381B1 (hu) * | 2014-02-17 | 2016-03-29 | Richter Gedeon Nyrt | Ipari eljárás szteroid intermedier előállítására |
| CA2966753A1 (en) | 2014-11-17 | 2016-05-26 | Arno Therapeutics, Inc. | Onapristone extended-release compositions and methods |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| CA3008422A1 (en) | 2015-12-15 | 2017-06-22 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
| WO2017172596A1 (en) | 2016-03-28 | 2017-10-05 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| WO2018106914A1 (en) * | 2016-12-09 | 2018-06-14 | Repros Therapeutics Inc. | Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent |
| CA3077308A1 (en) | 2017-09-27 | 2019-04-04 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
| PL3813800T3 (pl) | 2018-06-29 | 2025-08-18 | Incyte Corporation | Formulacje inhibitora axl/mer |
| RU2679625C1 (ru) * | 2018-11-08 | 2019-02-12 | Ильясов Шамиль Сионович | ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-6-ОКСА-7β-МЕТИЛ-D-ГОМО-8α-ЭСТРА-1,3,5(10)-ТРИЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ВКЛЮЧАЯ ТРИЖДЫ-НЕГАТИВНУЮ ФОРМУ, И СПОСОБ ЕГО ПОЛУЧЕНИЯ |
| AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2377418A1 (fr) * | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
| ZA8231B (en) | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| US4780461A (en) | 1983-06-15 | 1988-10-25 | Schering Aktiengesellschaft | 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same |
| DE3347126A1 (de) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3506785A1 (de) | 1985-02-22 | 1986-08-28 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3625315A1 (de) | 1986-07-25 | 1988-01-28 | Schering Ag | 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| US5446178A (en) | 1987-03-18 | 1995-08-29 | Schering Aktiengesellschaft | Process for preparing 19,11β-bridged steroids |
| DE3708942A1 (de) | 1987-03-18 | 1988-09-29 | Schering Ag | 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3866410D1 (de) | 1987-04-24 | 1992-01-09 | Akzo Nv | 11-arylestranderivate und 11-arylpregnanderivate. |
| ATE85342T1 (de) | 1987-12-12 | 1993-02-15 | Akzo Nv | 11-arylsteroid-derivate. |
| DE3820948A1 (de) | 1988-06-16 | 1989-12-21 | Schering Ag | 10ss, 11ss-ueberbrueckte steroide |
| DE3822770A1 (de) | 1988-07-01 | 1990-01-04 | Schering Ag | 13-alkyl-11ss-phenylgonane |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| DE3832303A1 (de) | 1988-09-20 | 1990-04-12 | Schering Ag | 11ss-phenyl-14ssh-steroide |
| DE3917274A1 (de) | 1989-05-24 | 1990-11-29 | Schering Ag | 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3921059A1 (de) | 1989-06-23 | 1991-01-10 | Schering Ag | 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel |
| DE4042007A1 (de) | 1990-12-22 | 1992-06-25 | Schering Ag | 6,7-modifizierte-11(beta)-aryl-4-estrene |
| US5407928A (en) | 1990-08-15 | 1995-04-18 | Schering Aktiengesellschaft | 11β-aryl-gona-4,9-dien-3-ones |
| DE4038128A1 (de) | 1990-11-27 | 1992-06-04 | Schering Ag | 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
| ZA929315B (en) | 1991-12-20 | 1993-05-24 | Akzo Nv | 17-spirofuran-3'-ylidene steroids. |
| DE4216003A1 (de) | 1992-05-12 | 1993-11-18 | Schering Ag | Dissoziierte kompetitive Progesteronantagonisten |
| US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| DE4216004B4 (de) | 1992-05-12 | 2008-03-27 | Bayer Schering Pharma Akiengesellschaft | Verwendung kompetitiver Progesteronantagonisten |
| ATE209189T1 (de) | 1992-07-01 | 2001-12-15 | Ortho Pharma Corp | 1-arylsulfonyl-3-phenyl-1,4,5,6- tetrahydropyridazinen |
| DE4332283A1 (de) | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4332284C2 (de) | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4434488A1 (de) | 1994-09-14 | 1996-03-21 | Schering Ag | Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US5576310A (en) | 1994-09-20 | 1996-11-19 | Jenapharm Gmbh | 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds |
| US5693646A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| DK0806952T3 (da) * | 1995-02-02 | 2003-06-16 | Schering Ag | Progesteronantagonister til fremstillingen af lægemidler til behandling af dysfunktionelle uterine blødninger |
| US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| WO1997041145A1 (en) * | 1996-05-01 | 1997-11-06 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | 21-substituted progesterone derivatives as new antiprogestational agents |
| US5753655A (en) | 1996-10-10 | 1998-05-19 | Ortho Pharmaceutical Corporation | 1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of preparation |
| DE19652408C2 (de) | 1996-12-06 | 2002-04-18 | Schering Ag | Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln |
| DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| DE19809845A1 (de) | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
| US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
| US6339098B1 (en) | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| DK1265911T3 (da) * | 2000-03-17 | 2008-09-29 | Us Gov Health & Human Serv | 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler |
| IN191020B (enExample) * | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| DE60115274T2 (de) * | 2000-10-18 | 2006-07-27 | Schering Ag | Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen |
| WO2007103510A2 (en) * | 2006-03-08 | 2007-09-13 | Danco Laboratories Llc | Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders |
| CA2682752C (en) * | 2007-04-05 | 2015-07-07 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
-
2009
- 2009-04-15 TW TW098112452A patent/TWI539953B/zh not_active IP Right Cessation
- 2009-04-27 CN CN2009801149792A patent/CN102099040B/zh not_active Expired - Fee Related
- 2009-04-27 US US12/990,210 patent/US20110053900A1/en not_active Abandoned
- 2009-04-27 KR KR1020107026594A patent/KR101349737B1/ko not_active Expired - Fee Related
- 2009-04-27 CA CA2722637A patent/CA2722637C/en not_active Expired - Fee Related
- 2009-04-27 JP JP2011507559A patent/JP5576362B2/ja not_active Expired - Fee Related
- 2009-04-27 ME MEP-2010-181A patent/ME01122B/me unknown
- 2009-04-27 MX MX2010011273A patent/MX2010011273A/es not_active Application Discontinuation
- 2009-04-27 MY MYPI2010004824A patent/MY161549A/en unknown
- 2009-04-27 UA UAA201014040A patent/UA101192C2/uk unknown
- 2009-04-27 EP EP15179121.7A patent/EP2974772A1/en not_active Withdrawn
- 2009-04-27 WO PCT/US2009/041836 patent/WO2009134723A1/en not_active Ceased
- 2009-04-27 BR BRPI0911112A patent/BRPI0911112A2/pt not_active Application Discontinuation
- 2009-04-27 NZ NZ589534A patent/NZ589534A/xx not_active IP Right Cessation
- 2009-04-27 EA EA201071250A patent/EA019224B1/ru not_active IP Right Cessation
- 2009-04-27 EP EP09739525A patent/EP2293798A1/en not_active Withdrawn
- 2009-04-27 AU AU2009241360A patent/AU2009241360B2/en not_active Ceased
- 2009-04-28 AR ARP090101509A patent/AR071419A1/es unknown
- 2009-04-28 CL CL2009001011A patent/CL2009001011A1/es unknown
-
2010
- 2010-10-20 IL IL208845A patent/IL208845A/en not_active IP Right Cessation
- 2010-10-26 ZA ZA2010/07648A patent/ZA201007648B/en unknown
- 2010-10-27 NI NI201000184A patent/NI201000184A/es unknown
-
2014
- 2014-05-23 US US14/286,535 patent/US20140343022A1/en not_active Abandoned
-
2016
- 2016-08-03 IL IL247093A patent/IL247093A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518883A5 (enExample) | ||
| JP2011518845A5 (enExample) | ||
| CN100349572C (zh) | 提高妇女睾酮和相关类固醇浓度的方法 | |
| US9370526B2 (en) | Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer | |
| CN1075375C (zh) | 合并应用于女性避孕的具黄体酮拮抗作用和抗雌激素作用的化合物 | |
| JP2010507685A5 (enExample) | ||
| CN1905885A (zh) | 包含雌激素和孕激素的延长应用组合 | |
| JP2018514593A5 (enExample) | ||
| IL292245B1 (en) | Polymorphic forms of rad1901-2hcl | |
| MY200490A (en) | Dhea compositions for treating menopose | |
| JP2013523683A5 (enExample) | ||
| Barros-Oliveira et al. | Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review | |
| AR071419A1 (es) | Composiciones y metodos de tratamiento del cancer de mama | |
| RU2013118325A (ru) | Лечение рака молочной железы | |
| CN1652798A (zh) | 连续抑制硫酸酯酶的孕激素的激素替代疗法 | |
| US20220031657A1 (en) | Pharmaceutical combination comprising lsz102 and ribociclib | |
| JP2013500324A5 (enExample) | ||
| WO2019106604A1 (en) | Pharmaceutical combination comprising lsz102 and alpelisib | |
| RU2004121162A (ru) | Применение анастрозола для лечения женщин в постклимактерическом периоде, которые страдают ранним раком молочной железы | |
| ES2320662T3 (es) | Hormonoterapia restitutiva y tratamiento para la depresion con dienogest. | |
| US20240316064A1 (en) | Use of estretol as a treatment for endometriosis | |
| CN103599108B (zh) | 齐墩果酸在制备预防和治疗胆汁淤积症药物中的应用 | |
| US20080261929A1 (en) | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases | |
| US20090029954A1 (en) | Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen | |
| JP2024506348A (ja) | Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療 |